CARCINOGENESIS, published by Oxford University Press, is a premier journal dedicated to the nuanced field of cancer research. With an ISSN of 0143-3334 and an E-ISSN of 1460-2180, this esteemed journal plays a crucial role in disseminating high-quality research findings since its inception in 1980, making it a cornerstone in the exploration of carcinogenic processes. As of 2023, it stands out with a commendable Q2 ranking in Cancer Research and a Q1 ranking in Medicine (miscellaneous), reflecting its significant impact in advancing knowledge in these vital areas. Supported by a strong Scopus ranking, specifically holding the 61st position out of 230 in Biochemistry, Genetics, and Molecular Biology within Cancer Research, CARCINOGENESIS provides researchers, healthcare professionals, and students access to peer-reviewed articles that cover a broad spectrum of topics related to cancer etiology, prevention, and treatment. Although it is not an open-access journal, its commitment to excellence ensures that every published article contributes meaningfully to the global fight against cancer, making it an essential resource for those engaged in cutting-edge cancer research.

BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, published by Elsevier, serves as a pivotal journal in the fields of biochemistry and biophysics, with a long-standing history dating back to 1956. This esteemed publication, bearing the ISSN 0304-4165 and E-ISSN 1872-8006, continuously contributes to advancing our understanding of complex biological processes through rigorous research articles and reviews. It notably holds a distinguished position with a Q2 classification in Biochemistry and a Q1 ranking in Biophysics for 2023, reflecting its high relevance and impact within these scientific domains. The journal is also recognized within the Scopus metrics, taking a rank of #40 out of 152 in Biophysics and #173 out of 438 in Biochemistry, thus placing it in the 74th and 60th percentiles respectively. Academics and professionals in the life sciences will find this journal an essential resource for current research, cutting-edge techniques, and comprehensive reviews aimed at enhancing the understanding of biological functions. While BIOCHIMICA ET BIOPHYSICA ACTA is not an open-access journal, it remains a cornerstone publication for those seeking to stay at the forefront of biochemical and biophysical research.

The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

The JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, published by BMC, is a leading open-access journal dedicated to advancing the field of cancer research and oncology. Since its inception in 1982, this esteemed journal has fostered innovation and collaboration in the scientific community, as evidenced by its outstanding impact factor and position in the Q1 quartile for both Cancer Research and Oncology categories in 2023. With a proud commitment to disseminating high-quality research, the journal operates under an open-access model, ensuring that findings are readily accessible to researchers, healthcare professionals, and students worldwide. The journal has established a distinguished reputation, ranking 23rd out of 404 in Medicine oncology and 16th out of 230 in Biochemistry, Genetics, and Molecular Biology (cancer research), showcasing its importance and influence in guiding the future of cancer treatment and research. With the aim of bridging experimental and clinical research, this journal invites submissions that push the boundaries of our understanding of cancer biology and therapy.

MOLECULAR CANCER THERAPEUTICS, published by the American Association for Cancer Research, is a premier journal dedicated to advancing the field of cancer research and therapy since 2001. With a notable impact factor reflecting its high-quality content, this journal stands out in the Q1 category for both Cancer Research and Oncology as of 2023. Researchers, clinicians, and students interested in innovative treatment strategies and molecular mechanisms can find valuable insights within its pages, bolstered by a rigorous peer-review process and a global perspective on cancer therapeutic developments. Although the journal operates under a subscription model, it provides comprehensive access to cutting-edge studies and reviews that drive forward the understanding of cancer biology and treatment modalities. The journal's impressive Scopus rankings further validate its influence within both oncology and the broader cancer research community, making it an indispensable resource for anyone committed to combating cancer through science.

Advances in Cancer Biology-Metastasis is an emerging journal published by Elsevier, aimed at advancing our understanding of the complexities of cancer biology, with a specific focus on the mechanisms and pathways related to metastasis. With an E-ISSN of 2667-3940, this journal offers a platform for researchers, professionals, and students in the fields of Cancer Research and Cell Biology to disseminate innovative findings and discuss novel therapeutic approaches. Though currently classified in the Q4 quartile across both Cancer Research and Cell Biology categories, the journal aspires to enhance its impact through rigorous peer review and high-quality publication. Positioned to cover the years from 2021 to 2024, it seeks to bridge gaps in foundational knowledge and promote collaborative research efforts that could pivot the current understanding of cancer metastasis. Researchers are encouraged to take advantage of this platform to advocate for advancements in cancer biology, making significant contributions that can influence both academic and clinical practices.

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

Cancer Research, published by the American Association for Cancer Research, is a premier journal in the field of oncology, renowned for its commitment to advancing cancer research since its inception in 1941. With an impressive impact factor reflecting its vital role in the field, this journal consistently ranks in the Q1 quartile for both Cancer Research and Oncology, positioning it among the top 7.5% of journals in these categories. The journal serves as a crucial platform for researchers, professionals, and students to disseminate and gain insights into groundbreaking studies that shape our understanding of cancer biology, prevention, diagnosis, and treatment. While it is not an open-access publication, its rigorous peer-review process ensures that only high-quality research is published, thus maintaining a standard of excellence in the scientific community. With a strong legacy and an ever-expanding influence, Cancer Research continues to be essential for anyone dedicated to the fight against cancer, showcasing cutting-edge research that drives scientific discovery and innovation.

Journal of Cellular and Molecular Medicine, published by Wiley, stands at the forefront of research excellence in the fields of cell biology and molecular medicine. With an impressive impact factor reflected in its 2023 Q2 category ranking for both Cell Biology and Molecular Medicine, this journal provides a vital platform for researchers and professionals alike, fostering innovative findings and groundbreaking discoveries since its inception in 2000. Maintaining an open access policy since 2012, the journal ensures that knowledge is freely disseminated, promoting collaboration and progress across the scientific community. With robust rankings in the Scopus database, including a position within the top 85th percentile in Molecular Medicine, the journal remains committed to advancing understanding of cellular functions and their implications in health and disease. Researchers, professionals, and students will find a treasure of high-quality articles and reviews that not only catalyze academic dialogue but also contribute significantly to practical applications in the life sciences.